Advanced in Neuroendocrine Tumor

David A. Pattison

Butterfield St, 
Herston, QLD, AU 
Clinical Trials:Currently Recruiting for 1 Trial
Advanced in Neuroendocrine Tumor
Butterfield St, 
Herston, QLD, AU 
OverviewLocationsClinical Research

Overview

David Pattison practices in Herston, Australia. Mr. Pattison is rated as an Advanced expert by MediFind in the treatment of Neuroendocrine Tumor. His top areas of expertise are Insulinoma, Neuroendocrine Tumor, Prostate Cancer, and Metastatic Insulinoma.

His clinical research consists of co-authoring 67 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 11 articles and participated in 1 clinical trial in the study of Neuroendocrine Tumor.

Gender
Male

Locations

Butterfield St, Herston, QLD 4029, Australia
Other Locations
305 Grattan Street, Melbourne, VIC 3000, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase Ib/II Study of Combination Avelumab With Peptide Receptor Radionuclide Therapy or Conventional Fractionated Radiotherapy in Patients With Metastatic Merkel Cell Carcinoma
A Phase Ib/II Study of Combination Avelumab With Peptide Receptor Radionuclide Therapy or Conventional Fractionated Radiotherapy in Patients With Metastatic Merkel Cell Carcinoma
Enrollment Status: Recruiting
Publish Date: February 14, 2025
Intervention Type: Radiation, Drug
Study Drug: Avelumab
Study Phase: Phase 1/Phase 2

67 Total Publications

Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial.
Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial.
Journal: The Lancet. Oncology
Published: April 26, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Pattison's expertise for a condition
ConditionClose
    View All 19 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile